Since 2010, new HIV infections have dropped 40 percent globally: from 2.2 million to 1.3 million in 2024. The UNAIDS 2025 report describes one of the greatest successes of modern medicine. For the first time since the epidemic's peak, the virus is losing ground in almost all regions of the world simultaneously.
1984 to 2024: Four Decades to the Turning Point
When HIV was identified as the cause of AIDS in 1984, there was no treatment, no prevention, and no reliable data on spread. The pandemic's peak came twenty years later: in 2004, 2.1 million people died of AIDS-related illnesses worldwide, and over three million people became newly infected each year.
The first turning point came in 1996: the introduction of combined antiretroviral therapy (ART), called triple therapy, transformed HIV from a death sentence into a manageable chronic disease. The second turning point came in 2003: the United States launched PEPFAR, the President's Emergency Plan for AIDS Relief, then the largest program ever launched to combat a single disease, with a starting budget of 15 billion dollars. Under international pressure, pharmaceutical manufacturers simultaneously slashed prices for generic ART, making annual treatment possible for under 100 dollars.
40 Percent Fewer Infections: What the Numbers Mean
According to UNAIDS Fact Sheet 2025, annual new infections fell from 2.2 million in 2010 to 1.3 million in 2024. The decline is particularly striking in Sub-Saharan Africa: there, where more than half of all new infections globally have historically occurred, the numbers dropped 56 percent.
The strongest progress affects children. In 2010, 310,000 children worldwide became newly infected with HIV; by 2024 that number had fallen to 120,000, a 62 percent decline. Two measures made this possible: antiretroviral therapy for pregnant women with HIV, which cuts transmission risk to the child from around 30 percent to below one percent, and expanded HIV testing in prenatal care, now standard in countries like Kenya and South Africa.
AIDS-related deaths have dropped 70 percent since the 2004 peak: from 2.1 million to around 630,000 in 2024. For people with HIV who have access to modern ART, life expectancy today approaches that of the general population.
Two caveats belong to the full picture. First: globally, 40.8 million people live with HIV according to UNAIDS. The number has risen since 2010 because modern therapies cut mortality so drastically that infected people live for decades. This requires sustainably funded health systems. Second: progress is unevenly distributed. In parts of Eastern Europe and Central Asia, the decline stagnates because stigma and drug epidemics block access to tests and treatment. According to UNAIDS, one in seven people with HIV still doesn't know they're infected.
Smallpox, Polio, Hepatitis C: What Other Successes Teach
The HIV response joins a series of global health successes showing what's possible when international coordination and sufficient financing align.
Humanity's greatest success came with smallpox. The WHO declared it eradicated in 1980 after a thirteen-year global vaccination campaign. The virus had killed around 300 million people in the twentieth century. Smallpox remains the only human disease ever completely eliminated.
Polio shows how far progress can go and where it stalls. In 1988, the WHO reported around 350,000 new polio cases annually worldwide. Through the Global Polio Eradication Initiative, involving the WHO, UNICEF, and Rotary International, the number fell by 2024 to fewer than 30 cases in the remaining endemic areas of Pakistan and Afghanistan. The hurdles are armed conflict and vaccine skepticism in certain regions.
Hepatitis C demonstrates what happens when no vaccine exists but cure is possible. Since 2014, direct-acting antivirals (DAAs) enable cure rates exceeding 95 percent. Roughly 50 million people worldwide remain chronically infected with Hepatitis C; the WHO has set the goal of eliminating the disease as a public health threat by 2030.
The common pattern: none of these successes arose spontaneously. All three required international coordination, massive funding, and the political will to make medicines available at affordable prices.
At This Pace: Below 500,000 Infections by 2030
UNAIDS has defined the 95-95-95 goal for 2030: 95 percent of people with HIV should know their status, 95 percent of them should be in treatment, and 95 percent of those treated should have viral loads too low to transmit. As of 2024, the world stands at 86-89-93. The final percentage points are historically the hardest because they reach the most difficult-to-reach populations.
If the current pace continues, new infections could fall below 500,000 annually by 2030. For comparison: in 1990, over three million people globally became newly infected each year. Eradicating the virus like smallpox is impossible without an effective vaccine; clinical trials for several mRNA-based HIV vaccine candidates are now underway.
Until then, progress depends on sustained financing. PEPFAR, the central US program with an annual budget around seven billion dollars, has repeatedly fought for its appropriations in recent years. Whether the progress of the past fourteen years holds will be decided not in laboratories, but in budget debates.